NextPoint Therapeutics

Executive Director Matthew Rausch, PhD, is presenting a poster atSITC Spring Scientific meeting. The poster explores the biology of the B7-H7 pathway and its potential to enhance T-cell–mediated anti-tumor responses. Reach out if you want to connect! #SITC

#InternationalWomensDay may have passed, but we’re still celebrating the women whose expertise and leadership drive our work at NextPoint. A snapshot of the people behind the science advancing precision immuno-oncology. #WomenInScience #WomenInBiotech

In Scrip’s “What Does 2026 Hold for Biopharma?” outlook, Tatiana Novobrantseva, CSO of NextPoint Therapeutics, shares her view on where oncology differentiation is headed, novel targets, deep biology, and modality-agnostic precision. Read more: bit.ly/4qXtqz2

Clinical entry of NPX372, a first-in-class B7-H7–targeted T cell engager, following U.S. IND clearance. The first-in-human study pairs an IgG-like CD3 bispecific with biomarker-driven patient selection to enable rapid clinical readouts in solid tumors. bit.ly/4bPxSvf

A look at CEO Ivan Cheung presenting at the JP Morgan Conference. Ivan shared our precision oncology strategy across T cell engager, ADC and checkpoint inhibitor, grounded in B7-H7 science and biomarker-driven patient selection. Energized by conversations and year ahead.

Jamie Strand, Ph.D., VP of Technical Operations, will speak at the CMC Strategy Forum North America on Jan 26, sharing how protein engineering and CMC-driven cell-line development support consistent, manufacturable B7-H7 biologics ready for the clinic. #CASSS #CMCNA2026

Ivan Cheung, CEO of NextPoint Therapeutics, will present at the 2026 J.P. Morgan Healthcare Conference on Jan 15 at 8:30 am in San Francisco. NextPoint is advancing precision therapeutics across multiple modalities targeting B7-H7.  #JPM2026

Data from NextPoint Therapeutics at #AACR-NCI-EORTC! NPX125, a B7-H7–targeting ADC, shows potent anti-tumor activity across solid tumor models. Reinforcing the promise of B7-H7 as a next-generation ADC target.

Headed to AACR-NCI-EORTC! Sr. Scientist Emilien Loeuillard will present a poster on NPX125, our novel ADC targeting B7-H7, a molecule central to tumor immune escape and highly expressed in tumors.

Join NextPoint Chief Scientific Officer Tatiana Novobrantseva and Director, Research and Development Melissa Hayes, at #SITC25 where they will be presenting the poster: TMIGD2 co-stimulation in a trispecific T cell engager elicits potent anti-tumor activity.

Heading to the ADC Linker & Conjugation Summit? Catch NextPoint CSO Tatiana Novobrantseva, PhD, on Aug 20 as she shares unique attributes of NPX125, a DAR8 B7-H7 targeting ADC with a novel linker. Can't make it? Let's connect!

NextPoint CSO Tatiana Novobrantseva, PhD, will moderate a plenary panel at the #IOSummit on Aug 13: "Accelerating IO through Target Discovery." Proud to see B7-H7 biology and smart target selection front and center in solid tumor IO.

NextPoint VP of Innovation Bijan Etemad-Gilbertson is heading to #BIO2025. We're advancing first-in-class precision therapeutic targeting the B7-H7 axis. Let’s connect in Boston to talk ADCs, TCEs & more.

CSO Tatiana Novobrantseva is featured in Databird’s “30 Visioneers Shaping the Future of Biotech in 2025.” She shares how NextPoint’s B7-H7 pathway approach offers a new angle on immune activation beyond PD-L1. Read more: databirdjournal.com/posts/redefini…

CMO Dr. Leena Gandhi, MD, PhD, speaks at Stanford's Stat4Onc Symposium on “Maintaining Flexibility in Dose Optimization in Early Phase Oncology Trials.” Don’t miss this expert-packed session on dose optimization across the drug lifecycle! #Stat4Onc #OncologyTrials

#AACR2025 Recap: B7-H7-ADC NPX125 ✅ Tumor-selective ✅Minimal normal tissue ✅High receptor density Strong interest in NPX125’s targeting & proprietary linker tech.

NextPoint to present pioneering preclinical data on NPX125, our B7-H7-targeted ADC, at #AACR2025. With proprietary linker tech + validated payload, NPX125 shows potent cytotoxicity + strong tumor activity. Learn more: bit.ly/3RzfOtO

NextPoint Co-Founder Dr. Gordon Freeman, pioneer of PD-L1/PD-L2, will speak at the Festival of Biologics on antibody-based checkpoint inhibition. A true leader in cancer immunotherapy. #FestivalOfBiologics #Immunotherapy

NextPoint is presenting 4 posters at #AACR2025! We're showcasing preclinical data on our B7-H7-targeted ADC and TCE programs. B7-H7 is upregulated across multiple cancer types with limited normal tissue expression— an ideal precision oncology target. bit.ly/4iWjmSN

NextPoint Co-founder Dr. Gordon Freeman & CSO Dr. Tatiana Novobrantseva will be speaking at IO360. Check them out during the New Tech in Transformational Biology track. #IO360Summit